摘要
目的探讨紫癜圣愈散对慢性特发性血小板减少性紫癜患者骨髓形态及外周血FOXP3表达的影响。方法应用显微镜观察巨核细胞数目及形态学分类,流式细胞仪测定CD4+CD25+FOXP3+在CD4+CD25+Treg中的比例。结果慢性特发性血小板减少性紫癜组治疗前骨髓巨核细胞数增多,产板巨核细胞比例减低,外周血CD4+CD25+FOXP3+表达的比例较正常对照组明显降低;紫癜圣愈散治疗后的巨核细胞数减少,产板巨核细胞比例明显增多,外周血CD4+CD25+FOXP3+比例增多。结论紫癜圣愈散对慢性特发性血小板减少性紫癜有促进其骨髓巨核细胞成熟及CD4+CD25+FOXP3+表达的作用,可能是紫癜圣愈散治疗CITP有效的作用机制之一。
Objective To investigate the Zidian Shengyu Pulvis on the bone marrow and peripheral blood of patients with chronic idiopathic thrombocytopenic purpura of FOXP3 expression effect. Methods Using microscope observation number of megakaryo- cyte and morphological classification, flow cytometry instrument measuring CD4+CD25+ FOXP3 + , CD4+CD25+ Treg in propor- tion. Results Chronic idiopathic thrombocytopenic purpura group of bone marrow megakaryocyte number increased before treat- ment, the p|atelet megakaryocyte proportion reduced, the proportion of peripheral blood CD4+CD25+ FOXP3 +expression was sig- nificantly lower than normal control group; Zidian Shengyu Pulvis megakaryocyte number decreased after the treatment, platelet megakaryocyte proportion increased significantly, peripheral blood CD4 + CD25 + FOXP3 + ratio increasing. Conclusion Zidian Shengyu Pulvis in chronic idiopathic thrombocytopenic purpura promotes the bone marrow megakaryocyte maturation and plays the role of CD4 + CD25 + FOXP3 + expression, and is likely to be the more effective one of the mechanisms of action treating CITP by Zidian Shengyu Pulvis.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2014年第3期553-555,共3页
Lishizhen Medicine and Materia Medica Research
基金
教育部春晖计划合作科研项目(No.Z2008-1-15009)